Human Pathology
Volume 39, Issue 8 , Pages 1239-1251 , August 2008

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma

  • C. Blake Gilks, MD

      Affiliations

    • Genetic Pathology Evaluation Centre of the Prostate Research Centre, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, and Gynecology Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E3
    • Corresponding Author InformationCorresponding author. Pathology and Laboratory Medicine, Vancouver General Hospital, 1st Floor JPPN, Vancouver, BC, Canada V5Z 1M9.
    • ,
  • Diana N. Ionescu, MD

      Affiliations

    • Genetic Pathology Evaluation Centre of the Prostate Research Centre, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, and Gynecology Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E3
    • ,
  • Steve E. Kalloger, BSC

      Affiliations

    • Genetic Pathology Evaluation Centre of the Prostate Research Centre, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, and Gynecology Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E3
    • ,
  • Martin Köbel, MD

      Affiliations

    • Genetic Pathology Evaluation Centre of the Prostate Research Centre, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, and Gynecology Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E3
    • Institute of Pathology, Charité Hospital, Berlin, 10117 Germany
    • ,
  • Julie Irving, MD

      Affiliations

    • Genetic Pathology Evaluation Centre of the Prostate Research Centre, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, and Gynecology Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E3
    • ,
  • Blaise Clarke, MD

      Affiliations

    • Genetic Pathology Evaluation Centre of the Prostate Research Centre, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, and Gynecology Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E3
    • ,
  • Jennifer Santos, RN

      Affiliations

    • Department of Medical Oncology and Gynecology Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6
    • ,
  • Nhu Le, PhD

      Affiliations

    • Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 1L3
    • ,
  • Veronika Moravan

      Affiliations

    • Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 1L3
    • ,
  • Kenneth Swenerton, MD

      Affiliations

    • Department of Medical Oncology and Gynecology Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6
    • ,
  • on behalf of the Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver, BC

Received 12 October 2007 ,Revised 4 January 2008 ,Accepted 8 January 2008.

References 

  1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529
  2. Silverberg SG, Bell DA, Kurman RJ, et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol. 2004;35:910–917
  3. Zaloudek C. “Tumors of the ovary”. In:  Fletcher CDM editors. Diagnostic Histopathology of Tumors. London: Churchill Livingstone; 2000;p. 567–642
  4. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 2002;21:407–411
  5. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–1518
  6. Itamochi K, Kigawa J, Sugimoya T, et al. Low proliferative activity my be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100:281–287
  7. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic cell type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584–2589
  8. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62:4722–4729
  9. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700–710
  10. Trimble EL, Fountain J, Birrer MJ. Recommendations of the 2005 Ovarian Cancer State of the Science Meeting. Gynecol Oncol. 2006;103:S26
  11. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19:7–15
  12. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of an universal grading system for ovarial epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer. 1998;82:893–901
  13. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: I. Prognostic significance of histopathologic features—problems involved in the architectural grading system. Gynecol Oncol. 1998;70:2–12
  14. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496–504
  15. Singer G, Shih Ie M, Truskinovsky A, Umudum H, Kurman RJ. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol. 2003;22:37–41
  16. Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223–1228
  17. Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484–486
  18. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol. 2005;29:218–224
  19. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst. 2000;92:699–708
  20. International Federation of Gynecology and Obstetrics . Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand. 1971;50:1–7
  21. In:  Tavassoli FA,  Devilee P editor. World Health Organization classification of tumours: Pathology and genetics. Tumours of the breast and female genital organs. Lyon, France: IARC Press; 2003;
  22. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723–728
  23. Gilks CB. Subclassification of ovarian surface epithelial carcinomas based on correlation of histological and molecular pathologic data. Int J Gynecol Pathol. 2004;23:200–205
  24. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998;58:1344–1347
  25. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 2001;61:8247–8255
  26. Cuatecasas M, Villaneuva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer. 1997;79:1581–1586
  27. Havrilesky L, Darcy KM, Hamdan H, et al. Prognostic significance of p53 overexpression and mutation in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3814–3825
  28. Katabuchi H, Tashiro H, Cho KR, Kurman RJ, Hedrick EL. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53. Int J Gynecol Pathol. 1998;17:54–60
  29. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst. 2002;94:61–67
  30. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002;94:1396–1406
  31. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol. 2002;99:3–10
  32. Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–368
  33. Hernandez E, Bhagavan BS, Parmeley TH, Rosenshein NB. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol Oncol. 1984;17:117–123
  34. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. Arch Pathol Lab Med. 1987;111:819–829
  35. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. APMIS. 1991;99:353–358
  36. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol. 1994;54:54–58
  37. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2005;46:468
  38. Kobel M, Langhammer T, Huttelmaier S, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol. 2006;19:581–587
  39. Alkushi A, Abdul-Rahman ZH, Lim P, Schulzer M, Coldman A, Kalloger SE, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol. 2005;29:295–304
  40. Ishioka S, Sagae S, Terasawa K, Sugimura M, Nishioka Y, Tsukada K, et al. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol. 2003;89:447–452
  41. Mayr D, Diebold J. Grading of ovarian carcinomas. Int J Gynecol Pathol. 2000;19:348–353
  42. Sato Y, Shimamoto T, Amada S, Asada Y, Hayashi T. Prognostic value of histologic grading of ovarian carcinomas. Int J Gynecol Pathol. 2003;22:52–56
  43. Malpica A, Deavers MT, Tomos C, et al. Inter-observer and intra-observer variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007;31:1203–1208

PII: S0046-8177(08)00030-0

doi: 10.1016/j.humpath.2008.01.003

Human Pathology
Volume 39, Issue 8 , Pages 1239-1251 , August 2008

Article Tools

* Image Usage & Resolution